Anticoagulation in Device-Detected Atrial Fibrillation with or Without Vascular Disease: a Combined Analysis of the NOAH-AFNET 6 and ARTESiA Trials.
Renate B. Schnabel,Juan Benezet-Mazuecos,Nina Becher,William F. McIntyre,Alexander Fierenz,Shun Fu Lee,Andreas Goette,Dan Atar,Emanuele Bertaglia,Alexander P. Benz,Gregory Chlouverakis,David H. Birnie,Wolfgang Dichtl,Carina Blomstrom-Lundqvist,A. John Camm,Julia W. Erath,Emmanuel Simantirakis,Valentina Kutyifa,Gregory Y. H. Lip,Philippe Mabo,Eloi Marijon,Lena Rivard,Ulrich Schotten,Marco Alings,Susanne Sehner,Tobias Toennis,Cecilia Linde,Panos Vardas,Christopher B. Granger,Antonia Zapf,Renato D. Lopes,Jeff S. Healey,Paulus Kirchhof European Heart Journal（2024）
Key words
Atrial fibrillation,Device-detected atrial fibrillation,Oral anticoagulation,Trial,Stroke
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper